Abstract P2-09-22: Use of a functional signal profiling test with high sensitivity and specificity to determine the prevalence of abnormal HER2-driven signaling activity in the HER2-negative breast cancer patient population: New patient group may benefit from HER2 therapy

2018 ◽  
Author(s):  
LG Laing ◽  
DJ Burns ◽  
IA MacNeil ◽  
BE Rich ◽  
S Myhre ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patient ◽  
Breast Cancer Patient ◽  
Sensitivity And Specificity ◽  
Patient Group ◽  
Patient Population ◽  
High Sensitivity ◽  
Signaling Activity

Vinorelbine plus capecitabine in a heavily pretreated HER2 negative metastatic breast cancer patient population: MCEPASTEBIN.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e13122-e13122
Author(s):  
Alfredo Enrique Torres ◽  
Charles L. Vogel ◽  
Jeremy Ramdial ◽  
Reshma L. Mahtani ◽  
Ana Sandoval-Leon
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Cancer Patient ◽  
Breast Cancer Patient ◽  
Patient Population ◽  
Metastatic Breast ◽  
Metastatic Breast Cancer Patient ◽  
Heavily Pretreated

Analysis of Demographic and Tumor Characteristics of an Inner City Breast Cancer Patient Population Compared with Patients Treated in National Surgical Adjuvant Breast and Bowel Project Trials

2010 ◽  
Vol 76 (6) ◽  
pp. 640-643
Author(s):  
Alfred J. Colfry ◽  
Timothy Humphries ◽  
George M. Fuhrman
Keyword(s):  
Breast Cancer ◽  
Cancer Patient ◽  
Inner City ◽  
Breast Cancer Patient ◽  
Tumor Size ◽  
Patient Population ◽  
Nodal Status ◽  
Tumor Characteristics ◽  
Receptor Status ◽  
Her 2

In June of 2008 we initiated a breast clinic designed to serve patients regardless of funding status. We analyzed age, race, tumor size, nodal status, estrogen, progesterone, and her-2-neu status. We compared our results to NSABP B-06 (nodal status), B-15 (estrogen, progesterone, and Her-2-neu receptor status), B-18, and B-27 (age, race, and tumor size) to determine whether our patient population was similar to patients included in these trials. Forty-nine patients with newly diagnosed breast cancer were treated during our first year (53 total cancers). Eight patients had noninvasive cancer; 45 had invasive disease. The mean age was 52.2 ± 12.2 years compared to a mean age of 48.4 ± 9.8 years in the B-06 trial ( P = 0.005). Thirty six patients were African American (74%) compared to 10% and 12% in the NSABP B-18 and B-27 trials ( P < 0.00001). A total of 23 of our patients with invasive cancer had involved axillary lymph nodes which was statistically more common than the 35.3% of node positive patients in the B-06 trial ( P = 0.03). Tumor size (3.6 ± 3.3 cm), estrogen (54.4%), and progesterone (52.8%) receptor status were similar to NSABP trials. Only 6 (13.3%) of our patients were considered Her-2-neu positive compared to 29.4 % in the B-15 trial which was significantly less prevalent ( P = 0.02). Significantly different demographic and tumor characteristics were identified in our inner city breast cancer patient population compared to NSABP patients. These results question the validity of using recommendations from large cooperative group trials in the development of treatment plans for our inner city patient population.

scholarly journals Do participants in major, practice-changing breast cancer trials reflect the breast cancer patient population?

Trials ◽  
2013 ◽  
Vol 14 (S1) ◽  
Author(s):  
Shaun Treweek ◽  
Ruth Dryden ◽  
Colin McCowan ◽  
Alison Harrow ◽  
Alastair Thompson
Keyword(s):  
Breast Cancer ◽  
Cancer Patient ◽  
Breast Cancer Patient ◽  
Patient Population ◽  
Cancer Trials

Do participants in adjuvant breast cancer trials reflect the breast cancer patient population?

2015 ◽  
Vol 51 (8) ◽  
pp. 907-914 ◽  
Author(s):  
Shaun Treweek ◽  
Ruth Dryden ◽  
Colin McCowan ◽  
Alison Harrow ◽  
Alastair M. Thompson
Keyword(s):  
Breast Cancer ◽  
Cancer Patient ◽  
Breast Cancer Patient ◽  
Patient Population ◽  
Adjuvant Breast Cancer ◽  
Cancer Trials
Sign in / Sign up

Export Citation Format

Share Document